Covid-19

Human eye
#Clinical trials #Comment #Covid-19 #Eye health

Innovative delivery: sustained ophthalmic steroids in diabetic macular edema 

Listen to this article on the DDW Podcast: Professor Sobha Sivaprasad, Professor of Retinal Clinical Studies, UCL Institute of Ophthalmology, and Consultant Ophthalmologist, Moorfields Eye Hospital, UK discusses unmet needs in DME therapeutics and how they could be addressed by sustained release ophthalmic steroids administered with novel suprachoroidal drug delivery methods.  Diabetic eye… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trends & Analysis

#Comment #Covid-19 #Genetics #Genomics #Public health #Research

Genomics boosts understanding of Covid-19 severity and susceptibility

Listen to this article on the DDW Podcast: The Covid-19 Host Genetics Initiative carried out one of the largest genome-wide association studies ever. It involved meta-analysis of nearly 50,000 Covid-19 patients and two million uninfected controls. Dr Hamdi Mbarek, Lead Analyst of the Qatari dataset explains how the initiative improved knowledge… Read More

#Covid-19 #Editor's Choice #Exclusive Content #News #Opinion #Trends & Analysis

#Comment #Covid-19 #Drug development #Drug discovery

From the editor: Courage and curiosity in collaboration 

Collaboration within the drug discovery sector is well documented, says Lu Rahman. During the Covid-19 pandemic we have seen great examples. Take Pfizer and BioNTech or the work between Carterra and Eli Lilly Company to create bamlanivimab, a Covid-19 therapeutic. Collaborative work has created vaccines and therapeutics which are… Read More

#Editor's Choice #News #Opinion

#Antibodies #Biotherapeutics #Covid variants #Covid-19 #Omicron

Antibody neutralises Omicron and Delta in live virus studies 

Revelar Biotherapeutics and Twist Bioscience have announced that RBT-0813 binds to and neutralises the Omicron and Delta variants of SARS-CoV-2 in live virus studies.   What is RBT-0813?  RBT-0813 is a bispecific antibody discovered by Twist Biopharma and licensed to Revelar Biotherapeutics that targets epitopes on the SARS-CoV-2 spike protein. Revelar has continued… Read More

#News #Trending News

#Collaboration #Covid-19 #Mouse models #Research

Agreement paves the way for better mouse models to study Covid-19 

Scientists at La Jolla Institute for Immunology (LJI) and Charles River Laboratories International are launching a new project to uncover how different cells in the human immune system respond to SARS-CoV-2, the virus that causes Covid-19.   The research  This new mouse model has been engineered… Read More

#Covid-19 #News

#Covid booster #Covid-19 #Immunology / Virology & Vaccines #Omicron #RNA #T-Cells

Early data for multivariant Covid-19 vaccine booster shows promise  

The first results of an early trial of a multivariant Covid-19 vaccine booster, launched in Manchester in September 2021, has shown it is driving a comprehensive immune response.  The results  US-based biotechnology company Gritstone bio, in collaboration with The University of Manchester and Manchester University… Read More

#Covid-19 #News

#Covid variants #Covid-19 #Immunology / Virology & Vaccines

New data on antiviral efficacy against SARS-CoV-2 variants  

Marinomed Biotech, an Austrian biotech company, has announced results of the antiviral efficacy of iota-carrageenan (Carragelose) against the original SARS-CoV-2 strain and variants of concern (VOC), including the Delta variant. This has been published in the International Journal of Molecular Sciences.   Collaboration   The peer-reviewed study is… Read More

#Covid-19 #News #Trending News

#Cancer research #Covid variants #Covid-19 #Immunology / Virology & Vaccines #Tumours

Third Covid-19 vaccine boosts immunity for most cancer patients  

According to new results published as a correspondence in Cancer Cell, nearly 100% of cancer patients with solid tumours have antibodies effective against the Delta variant after a third dose of Covid-19 vaccine.  What does this mean?  The new findings highlight a proportion of patients with blood… Read More

#News

#Covid-19 #Healthcare #Immunology / Virology & Vaccines #Public health

European Commission authorises Novavax Covid-19 vaccine

Novavax has been granted conditional marketing authorisation by the European Commission (EC) for Nuvaxovid Covid-19 vaccine.  Context  The vaccine is for active immunisation to prevent Covid-19 caused by SARS-CoV-2 in individuals 18 years of age and older and the authorisation follows the European Medicines Agency’s (EMA) Committee for Medicinal… Read More

#Covid-19 #News #Trending News

#Covid-19 #Research study #T-Cells

How is Japan keeping Covid-19 cases so low? 

Research by the Riken Institute in Tokyo, published in the British journal Communications Biology, offers an explanation for Japan’s success in tackling the Covid-19 pandemic when compared with other countries. The research is a piece of the puzzle of why there remains relatively low rates of death and serious… Read More

#Covid-19 #News #Trending News

#Covid variants #Covid-19 #Omicron #Research study

Qatari research proves natural immunity theory for Covid-19 

New research from Qatar, published in the New England Journal of Medicine, has found that the natural immunity from prior infection of Covid-19 has a 92% efficacy against reinfection of the Beta variant, and a 98% efficacy against reinfection of the Alpha variant.   The study … Read More

#Covid-19 #News

#Covid-19 #Healthcare #Immunology / Virology & Vaccines #Public health #Research

NIH scientists urge pursuit of universal coronavirus vaccine 

Physician-scientists of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), have published a paper in The New England Journal of Medicine which suggests that in order to counter future coronavirus outbreaks, the global scientific and medical research community should focus… Read More

#News #Trending News

#Biopharmaceuticals #Covid-19

Noorik Biopharmaceuticals to develop treatment for severe Covid-19 

Noorik Biopharmaceuticals, a clinical-stage biopharmaceutical company repurposing micro-dose ambrisentan for the treatment of kidney, liver, and respiratory diseases, signed a contract with the Federal Government of Switzerland to develop ambrisentan as a treatment for patients with severe Covid-19.   Why?  The investment, under the Federal Funding Programme for Covid-19 Medicines initiative, will enable… Read More

#Covid-19 #News

#Antivirals #Covid-19 #FDA #Immunology / Virology & Vaccines #Pfizer

Pfizer Covid pill effective against severe disease 

Pfizer has announced results from an analysis of 2,246 adults enrolled in its Phase II/III EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk Patients) trial of its novel Covid-19 oral antiviral candidate Paxlovid (nirmatrelvir [PF-07321332] tablets and ritonavir tablets).   The results   These results show that  Paxlovid significantly reduced the… Read More

#Covid-19 #News #Trending News

#Biotherapeutics #Covid-19

Pharmacokinetic study for developing kidney disease and injury therapies 

XORTX Therapeutics has chosen Altasciences to conduct a pharmacokinetic bridging study in support of the XRx-008 programme for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injury associated with Covid-19.   Context   XORTX’s formulations of xanthine oxidase inhibitors are aimed at reducing uric acid levels in order… Read More

#News

#Covid variants #Covid-19 #Immunology / Virology & Vaccines #Omicron

Vaccines induce fewer neutralising antibodies against Omicron

Researchers from the University of Oxford have analysed the impact of the Omicron Covid-19 variant of concern on one of the immune responses generated by vaccination.  The study  Using blood samples from individuals who had previously received two doses of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines as part… Read More

#Covid-19 #News